

---

---

UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: March 16, 2022

Commission File Number: 001-38974

**BIOPHYTIS S.A.**  
(Translation of registrant's name into English)

---

Stanislas Veillet  
Biophytis S.A.  
Sorbonne University—BC 9, Bâtiment A 4ème étage  
4 place Jussieu  
75005 Paris, France  
+33 1 44 27 23 00  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

**EXHIBIT LIST**

<b>Exhibit</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release dated March 16, 2022.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BIOPHYTIS S.A.**

Date: March 16, 2022

By: /s/ Stanislas Veillet

\_\_\_\_\_  
Name: Stanislas Veillet

Title: Chairman and Chief Executive Officer

---



*Press Release*

**Biophytis will participate in a key conference  
on mobility for the elderly**

**Paris (France), Cambridge (Massachusetts, United States), March 16, 2022 – 8 A.M** – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces its participation to a conference regarding the development of mobility therapies for the elderly, organized by the National Institute on Aging based in Baltimore, USA.

The management of Biophytis will present the progress of its drug candidate and will meet with public and private players in the field of mobility for the elderly, all potential partners in the context of the upcoming start of Sarconeos (BIO 101) phase III in sarcopenia.

The conference, named **“Development of function promoting therapies: public health need, molecular targets, and drug development”** will be held online from the 20<sup>th</sup> to the 22<sup>nd</sup> of March, 2022. This conference is organized by the National Institute on Aging (NIA), a branch of the National Institutes of Health (NIH), based in the United States.

Headquartered in Baltimore, Maryland, NIA is coordinating a broad scientific effort to understand the nature of aging and enable elderly people to live a healthy and active life.

**About BIOPHYTIS**

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia with a positive Phase 2 clinical trial performed in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

The company is based in Paris, France, and Cambridge, Massachusetts. The company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADS (American Depositary Shares) are listed on Nasdaq (Ticker BPTS – ISIN: US09076G1040).

For more information visit [www.biophytis.com](http://www.biophytis.com)

---



*Press Release*

**Disclaimer**

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risks and uncertainties the Company is to face" section from the Company's 2021 Half Year Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)) and as exposed in the "Risks Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

**Biophytis Contact for Investor Relations**

Evelyne Nguyen, CFO  
[investors@biophytis.com](mailto:investors@biophytis.com)

**Media Contacts**

[Antoine Denry : antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27  
[Agathe Boggio : agathe.boggio@taddeo.fr](mailto:agathe.boggio@taddeo.fr) – +33 7 62 77 69 42

---